Login to Your Account

Rigel ‘Fosta’ Child in Spotlight After R333 Fails Phase II

By Randy Osborne
Staff Writer

Friday, October 25, 2013

With Rigel Pharmaceuticals Inc.’s R333 kaput in Phase II trials for skin lesions in discoid lupus erythematosus patients, attention has turned from the topical JAK/SYK inhibitor to fostamatinib, an oral SYK inhibitor bound for Phase III trials in the first half of next year in immune thrombocytopenic purpura (ITP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription